Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 10/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4335410 | 0.86 | F2R (0.52) | F2RMAOBNPC1RAB9ABCHE | |
| Bromide SCHEMBL4344865 | 0.85 | F2R (0.51) | F2RMAOBNPC1RAB9ABCHE | |
| SCHEMBL14346241 | 0.83 | F2R (0.53) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL14346226 | 0.82 | F2R (0.67) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL14346235 | 0.82 | F2R (0.51) | F2RMAOBNPC1RAB9ABCHE | |
| Hydrochloric Acid SCHEMBL4352129 | 0.82 | F2R (0.53) | F2RMAOBBCHEMAOAACHE | |
| Bromide SCHEMBL4338928 | 0.81 | F2R (0.66) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL4335413 | 0.81 | F2R (0.41) | F2RWDR5MEN1KMT2A | |
| SCHEMBL14346245 | 0.74 | F2R (0.53) | F2RMAOBBCHEMAOAACHE | |
| SCHEMBL14346346 | 0.73 | F2R (0.43) | F2RNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391456-B1 | 2-IMINOIMIDAZOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-7304083-B2 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004197-A1 | 2-iminoimidazole derivatives (2) | H1-2, H1-3, H1-4 | F2R 2393/4885MAOB 2255/4885NPC1 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.